<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00774475</url>
  </required_header>
  <id_info>
    <org_study_id>000</org_study_id>
    <nct_id>NCT00774475</nct_id>
  </id_info>
  <brief_title>Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition</brief_title>
  <acronym>DANTE</acronym>
  <official_title>Optimization of Antiplatelet Therapy With Clopidogrel on the Basis of the Extent of Platelet Inhibition in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy Undergoing PCI With Stent Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tuscany Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florence</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy (reduction of major ischemic events at
      6 and 12 months of follow-up) of a tailored clopidogrel therapy in patients with UA/NSTEMI
      undergoing PCI with stent implantation and wiht a documented residual platelet reactivity
      assessed by a point of care system (VerifyNow P2Y12).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies documented the presence of a high variability in the individual response to
      antiplatelet therapies in terms of extent of platelet function inhibition. This laboratory
      finding is the so-called aspirin or clopidogrel resistance which we prefer to define residual
      platelet reactivity (RPR) on antiplatelet therapy.

      A growing body of evidence is demonstrating the clinical relevance of this laboratory
      parameter, i.e. patients with RPR are at higher risk of a subsequent adverse cardiovascular
      event.

      In particular, it has been demonstrated that RPR measured by light transmittance aggregometry
      induced by ADP or by the point of care assay VerifyNow P2Y12 identifies patients which, after
      coronary revascularization with stent implantation, at higher risk of a potentially
      catastrophic event such as stent thrombosis.

      No randomized trials are available in the literature on the efficacy and safety of an
      antiplatelet therapy tailored on the extent of platelet function inhibition.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of MACE (cardiovascular death, nonfatal myocardial infarction, target lesion vessel revascularization by PCI or coronary bypass)</measure>
    <time_frame>6 and 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis with angiographic confirmation; platelet function assessed by VerifyNow P2Y12 1 week after the randomization</measure>
    <time_frame>1 week; 6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">442</enrollment>
  <condition>Unstable Angina</condition>
  <condition>NSTEMI</condition>
  <arm_group>
    <arm_group_label>1: standard therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>clopidogrel 75 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: doubled therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clopidogrel 150 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>comparison of different dosage of clopidogrel</intervention_name>
    <description>clopidogrel 75 mg/day versus clopidogrel 150 mg/day</description>
    <arm_group_label>1: standard therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doubled therapy</intervention_name>
    <description>clopidogrel 150 mg/day</description>
    <arm_group_label>2: doubled therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unstable or NSTEMI

        Exclusion Criteria:

        Previous bleeding events which have required blood transfusion

          -  PT- INR &gt;1.5

          -  Platelet count ≤ 100000/ mm3

          -  Hb &lt; 10 g/dl

          -  Previous TIA/stroke (ischemic or hemorrhagic or unknown)

          -  Body weight &lt; 60 Kg

          -  Creatinine levels ≥ 4 mg/dl

          -  Cerebral neoplasia

          -  Recent major trauma/surgery/head injury (within 3 previous weeks)

          -  Gastrointestinal hemorrhage in the last month

          -  Aortic dissection

          -  Known haemorrhagic diathesis

          -  Oral anticoagulant therapy

          -  Pregnancy or 1 week after delivery

          -  Uncontrolled hypertension (systolic &gt;180 mmHg or diastolic &gt;110 mmHg)

          -  Severe liver disease

          -  Infective endocarditis

          -  Major psychiatric disorders

          -  Alcool or drug abuse

          -  Active peptic ulcer Noncompressible arterial puncture within 14 days Prolonged
             cardiopulmonary resuscitation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gian Franco Gensini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florence</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianni Maria Santoro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ASL 10 Florence, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Niccolò Marchionni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Florence</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Antoniucci, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Ospedaliero-Universitaria Careggi</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Zuppiroli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ASL 10 Florence Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Cristina Landini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ASL 10 Florence Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosanna Abbate, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Florence</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gian Franco Gensini, MD</last_name>
    <phone>00390557949417</phone>
    <email>g.gensini@dac.unifi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rossella Marcucci, MD</last_name>
    <phone>00390557949420</phone>
    <email>rossella.marcucci@unifi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florence</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, Buonamici P, Gensini GF, Vergara R, Abbate R, Antoniucci D. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol. 2008 Aug 26;52(9):734-9. doi: 10.1016/j.jacc.2008.05.032.</citation>
    <PMID>18718420</PMID>
  </reference>
  <reference>
    <citation>Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol. 2007 Jun 19;49(24):2312-7. Epub 2007 Jun 4.</citation>
    <PMID>17572245</PMID>
  </reference>
  <reference>
    <citation>Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008 Apr;29(8):992-1000. doi: 10.1093/eurheartj/ehn046. Epub 2008 Feb 10.</citation>
    <PMID>18263931</PMID>
  </reference>
  <reference>
    <citation>Santoro GM, Carrabba N, Barchielli A, Balzi D, Marchionni N, Filice M, Valente S, Granelli M, Berni I, Buiatti E; AMI-Florence Working Group. Use and efficacy of abciximab in an unselected population with acute myocardial infarction treated with primary angioplasty: data from AMI-Florence registry. Atherosclerosis. 2007 Nov;195(1):116-21. Epub 2006 Sep 25.</citation>
    <PMID>16997308</PMID>
  </reference>
  <reference>
    <citation>Balzi D, Barchielli A, Buiatti E, Franceschini C, Lavecchia R, Monami M, Santoro GM, Carrabba N, Margheri M, Olivotto I, Gensini GF, Marchionni N; AMI-Florence Working Group. Effect of comorbidity on coronary reperfusion strategy and long-term mortality after acute myocardial infarction. Am Heart J. 2006 May;151(5):1094-1100.</citation>
    <PMID>16644342</PMID>
  </reference>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <last_update_submitted>October 23, 2008</last_update_submitted>
  <last_update_submitted_qc>October 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Gian Franco Gensini</name_title>
    <organization>University of Florence</organization>
  </responsible_party>
  <keyword>Clopidogrel therapy</keyword>
  <keyword>platelet function inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina, Unstable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

